Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies ClonoSEQ Expansion

Adaptive Biotechnologies has announced the expansion of its clonoSEQ process to include minimal residual disease analysis of cells harvested from patients with lymphoid cancers being prepared for autologous stem cell transplant. The expansion will allow physicians to prepare patients for autologous stem cell transplants by providing prognostic information that may potentially inform treatment decisions about maintenance post-transplant, Tom Willis, senior vice president and general manager of diagnostic products at Adaptive Biotechnologies, said in a statement. Physicians wishing to submit autograft samples should fill out the clonoSEQ MRD Test Requisition Form and submit samples using a clonoSEQ Specimen Kit to Adaptive's CLIA-certified, CAP-accredited laboratory in South San Francisco. Results will be available within seven days of sample receipt.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.